Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancerDeepa Maheswari Narasimhulu, Anna Fagotti, Giovanni Scambia, Amy L Weaver, Michaela McGree, Lorena Quagliozzi, Carrie Langstraat, Amanika Kumar, William Cliby
14 December 2022
Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancerMartina Aida Angeles, Emanuela Spagnolo, Bastien Cabarrou, Assumpció Pérez-Benavente, Antonio Gil Moreno, Frederic Guyon, Agnieszka Rychlik, Federico Migliorelli, Guillaume Bataillon, Anne-Sophie Navarro, Sarah Betrian, Gwenael Ferron, Alicia Hernández, Alejandra Martinez
29 November 2022
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 CohortLauren Shore Prescott, Ignace Vergote, Charlotte C Sun, Diane C Bodurka, Robert L Coleman
10 November 2022
Peritoneal carcinomatosis after minimally invasive surgery versus open radical hysterectomy: systematic review and meta-analysisJorge Hoegl, David Viveros-Carreño, Tatiana Palacios, Andres Gallego - Ardila, Jose Alejandro Rauh-Hain, Erick Estuardo Estrada, Florencia Noll, Kate Krause, Glauco Baiocchi, Lucas Minig, Carlos Fernando Grillo - Ardila, Rene Pareja
8 November 2022
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservationBeryl Manning-Geist, Sushmita Gordhandas, Anjelica Hodgson, Qin C Zhou, Alexia Iasonos, Dennis S Chi, Lora Ellenson, Carol A Aghajanian, Nadeem R Abu-Rustum, Mario Leitao, Kara Long, Maria M Rubinstein, Yukio Sonoda, Kaled Alektiar, Britta WeigeltSee the full list of authors
11 November 2022
Endometrial cancer after endometrial ablation: a systematic reviewTamara J Oderkerk, Mileen R D van de Kar, Karlijn M C Cornel, Marlies Y Bongers, Peggy M A J Geomini
14 November 2022
Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasiaJunyu Chen, Dongyan Cao, Jiaxin Yang, Mei Yu, Huimei Zhou, Ninghai Cheng, Jinhui Wang, Ying Zhang, Peng Peng, Keng Shen
11 November 2022
Drug repurposing as a potential source of innovative therapies in cervical cancerRica Capistrano I., Sonz Paul, Ingrid Boere, Pan Pantziarka, Supriya Chopra, Remi A Nout, Gauthier Bouche
22 September 2022
Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinomaDimitrios Nasioudis, Spyridon A Mastroyannis, Emily M Ko, Ashley F Haggerty, Lori Cory, Robert L Giuntoli II, Sarah H Kim, Nawar A Latif
26 July 2022
Primary mucinous ovarian cancer: options for surgery and chemotherapyKatherine C Kurnit, Michael Frumovitz
13 October 2022